Exdensur (depemokimab)

The anatomy of a Drug to Watch

Key evaluation criteria in chronic respiratory diseases and how Exdensur was selected as a Drug to Watch 2026

Clarivate analysts rely on actionable data and market intelligence from our suite of products to identify each year's Drugs to Watch — the blockbusters and treatment paradigm-shifters.

Identifying the next breakthroughs for chronic respiratory diseases

This complex market comprises diverse patient populations, multiple overlapping biologic classes and adherence- and convenience-driven differentiation, making it challenging to predict which therapies will meaningfully shift treatment paradigms. The first step is translating the evidence base into a clear view of which drugs are likely to launch and succeed within the Drugs to Watch target timeframe.

Mapping the therapy landscape: Cortellis Competitive Intelligence

Our analysts gain a broad view of the status and potential success of drugs for chronic respiratory diseases using Cortellis Competitive Intelligence, which:

- Covers the entire development lifecycle
- Provides clinical, deals, regulatory and patent intelligence for each drug and company
- Predicts the likelihood and timing of drug launches with the Drug Timeline & Success Rates statistical modeling methodology and ML-based predictive analytics

By reviewing the therapeutic landscape, Clarivate analysts narrow the field to a short list of assets that warrant deeper investigation as Drugs to Watch.

Figure 1: Comparison of drug timelines and success rates by therapeutic area and location determined by Cortellis Competitive Intelligence, Drug Timeline & Success Rates Prediction.

Exdensur (depemokimab)

First-mover advantage with market-shaping dosing convenience



Cortellis Competitive Intelligence

Demonstrates how Exdensur differentiates in a crowded IL-5 market with ultra-long-acting convenience and efficacy.

- Only IL-5 inhibitor with ultra-long-acting 6-month dosing among phase 3 or approved compounds
- 59% reduction in exacerbations vs NUCALA (mepolizumab; GSK) or FASENRA® (benralizumab; AstraZeneca)
- 95% probability of success for Exdensur in the E.U. based on Cortellis AI analysis of precedent

Learn more

Cortellis Regulatory Intelligence and AI Regulatory Assistant

Highlights regulatory approvals across major markets, reinforcing 2026 launch readiness and supporting strong positioning in eosinophilic respiratory indications.

- Approved in four markets (E.U., Japan, U.K., U.S.) for asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
- Multi-jurisdictional approvals confirming a de-risked regulatory pathway
- Established regulatory momentum enabling rapid market access and lifecycle expansion opportunities

Learn more

Disease Landscape & Forecast

Shows large, addressable asthma and CRSwNP populations, with ultra-long-acting convenience of Exdensur supporting preferred step-up positioning and greenfield expansion opportunity.

- Projected asthma therapy market growth: from $24.5bn in 2024 to $30.6bn in 2034 in the G7 markets
- ~5-8m eligible patients in the high-severity subset of CRSwNP in the G7 market, with premium pricing justified by unmet need
- $525m in forecast sales by 2030, with peak sales of $900m-$1.2bn by 2034 following expansion to eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome

Learn more

Epidemiology Intelligence

Identifies how the IL-5–mediated patient population across asthma, CRSwNP and rare eosinophilic diseases supports meaningful revenue potential, with the dosing positioned to drive uptake.

- ~16.7m drug-treated prevalent cases of moderate-to-severe asthma in the G7 markets in 2025
- ~3m-5m diagnosed cases of CRSwNP in the G7 markets in 2025, with 20-30% annual recurrence rates and significant disease burden
- ~25k-40k diagnosed cases of EGPA and ~5k-10k diagnosed cases of hypereosinophilic syndrome in the G7 markets in 2025 (rare/orphan designation eligible)

Learn more





Summary of impact

Exdensur

Exdensur could reset expectations in IL-5–mediated disease management, transforming convenience into a primary competitive lever. Durable market share is supported by its first-mover positioning in ultra-long-acting IL-5 inhibition, rare disease expansion and established GSK commercial infrastructure.

Ready to see if your drug is one to watch?

Contact us to learn how integrating intelligence from multiple Clarivate products, powered by AI, drives confident predictions of the potential competitive impact of your drug on the market and patients' lives.

clarivate.com